|
|
 |
|
Viewing report
|
|
|
|
European Antidepressants Markets
Frost & Sullivan, June 2006
This Frost & Sullivan research service titled European Antidepressants Markets provides a detailed analysis of the antidepressants markets, with a description of key market drivers and restraints. An analysis of the product pipelines of leading companies as well as overall market forecasts are also provided. In this research, Frost & Sullivan’s expert analysts thoroughly examine the following markets: selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and other antidepressants.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Other antidepressants
Market Overview
Better Efficacy and Relatively Lesser Side-effects of SNRIs to Promote Continued Market Growth
The increasing incidence of depression and anxiety disorders in Europe is leading to greater focus on diagnosis and treatment options, thus contributing to the significance of antidepressants. Apart from this, antidepressants are being investigated for their utility in a number of central nervous system (CNS) disorders. As several antidepressants are also being prescribed off-label for a variety of disorders, such as phobias and menopause-related symptoms, among others, continued market developments are expected. Currently, growth in the market is strongly led by the performance of serotonin-norepinephrine reuptake inhibitors (SNRIs), a class of drugs that features limited generic competition and recently introduced brands. Besides, there are a small number of brands outside the selective serotonin reuptake inhibitors (SSRI) and SNRI classes of drugs that are augmenting overall market sales.
'In the future, growth in the market is expected to be driven primarily by SNRIs as well as other new classes of antidepressants,' says Sumanth Kambhammettu, the analyst of this research service. 'This can be attributed to the prevailing perception of greater efficacy and reduced side-effects of SNRIs in comparison to the SSRI class of drugs.' Increasing evidence linking SSRIs to instances of suicide among children and adolescents is also hampering the performance of this segment. Moreover, escalating generic competition is anticipated to result in increased market share of SNRIs and other novel antidepressants, thereby affecting the growth of the SSRI class of drugs that currently dominate the market.
Effective Product Life-cycle Management Crucial to Combat Intensifying Competition
'The maturity of the market, along with increasing parallel importation, reference pricing and rising generic competition are likely to hinder market progress,' remarks Mr. Kambhammettu. 'In view of surging healthcare costs, most of the European nations have implemented stringent cost -containing measures, resulting in intensifying pressure on profits.' Moreover, the implementation of regulatory standards such as the decentralisation of reimbursement policies in Italy and the reimbursement restrictions on certain drugs enforced by majority of the governments in Europe are crucial restraints.
Despite these challenges, the high level of unmet clinical needs and the presence of limited innovative drugs, combined with the potential for blockbuster products will continue to drive market expansion. Product life-cycle management will gain prominence and market participants will need to focus on strategically positioning their products early in the life cycle to generate maximum revenues in the patent exclusivity period. Furthermore, research will need to emphasise the expansion of product indications and prolong the life cycles of blockbuster molecules. Establishing marketing collaborations to implement aggressive marketing and product promotion will also become essential to gain a competitive edge in the market.
|
|
|
|
